nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—thyroid cancer—Graves' disease	0.864	1	CtDrD
Vandetanib—EPHA8—eye—Graves' disease	0.00165	0.0239	CbGeAlD
Vandetanib—EPHA5—eye—Graves' disease	0.00128	0.0185	CbGeAlD
Vandetanib—TYRO3—connective tissue—Graves' disease	0.00123	0.0178	CbGeAlD
Vandetanib—LYN—connective tissue—Graves' disease	0.00122	0.0177	CbGeAlD
Vandetanib—Interstitial lung disease—Propylthiouracil—Graves' disease	0.00118	0.108	CcSEcCtD
Vandetanib—Skin ulcer—Propylthiouracil—Graves' disease	0.00107	0.0979	CcSEcCtD
Vandetanib—FLT3—connective tissue—Graves' disease	0.00105	0.0151	CbGeAlD
Vandetanib—FLT4—eye—Graves' disease	0.000987	0.0143	CbGeAlD
Vandetanib—RIPK2—eye—Graves' disease	0.000981	0.0142	CbGeAlD
Vandetanib—EPHA5—pituitary gland—Graves' disease	0.000948	0.0137	CbGeAlD
Vandetanib—RIPK2—connective tissue—Graves' disease	0.000945	0.0137	CbGeAlD
Vandetanib—BMPR1B—adipose tissue—Graves' disease	0.000925	0.0134	CbGeAlD
Vandetanib—ERBB3—connective tissue—Graves' disease	0.000905	0.0131	CbGeAlD
Vandetanib—MKNK1—eye—Graves' disease	0.000882	0.0128	CbGeAlD
Vandetanib—AXL—eye—Graves' disease	0.000868	0.0126	CbGeAlD
Vandetanib—FMO3—eye—Graves' disease	0.000841	0.0122	CbGeAlD
Vandetanib—RET—connective tissue—Graves' disease	0.000839	0.0121	CbGeAlD
Vandetanib—AXL—connective tissue—Graves' disease	0.000836	0.0121	CbGeAlD
Vandetanib—BMPR1B—thyroid gland—Graves' disease	0.000801	0.0116	CbGeAlD
Vandetanib—STK35—adipose tissue—Graves' disease	0.000787	0.0114	CbGeAlD
Vandetanib—FYN—connective tissue—Graves' disease	0.000782	0.0113	CbGeAlD
Vandetanib—ABL2—pituitary gland—Graves' disease	0.00077	0.0111	CbGeAlD
Vandetanib—ABL2—adipose tissue—Graves' disease	0.000767	0.0111	CbGeAlD
Vandetanib—TEK—connective tissue—Graves' disease	0.000764	0.0111	CbGeAlD
Vandetanib—EGFR—adipose tissue—Graves' disease	0.000748	0.0108	CbGeAlD
Vandetanib—YES1—eye—Graves' disease	0.000733	0.0106	CbGeAlD
Vandetanib—FLT4—adipose tissue—Graves' disease	0.000729	0.0106	CbGeAlD
Vandetanib—RIPK2—pituitary gland—Graves' disease	0.000728	0.0105	CbGeAlD
Vandetanib—VEGFA—pituitary gland—Graves' disease	0.000726	0.0105	CbGeAlD
Vandetanib—RIPK2—adipose tissue—Graves' disease	0.000725	0.0105	CbGeAlD
Vandetanib—VEGFA—adipose tissue—Graves' disease	0.000723	0.0105	CbGeAlD
Vandetanib—FMO1—pituitary gland—Graves' disease	0.000722	0.0105	CbGeAlD
Vandetanib—FMO1—adipose tissue—Graves' disease	0.00072	0.0104	CbGeAlD
Vandetanib—IRAK4—pituitary gland—Graves' disease	0.000711	0.0103	CbGeAlD
Vandetanib—IRAK4—adipose tissue—Graves' disease	0.000708	0.0103	CbGeAlD
Vandetanib—YES1—connective tissue—Graves' disease	0.000706	0.0102	CbGeAlD
Vandetanib—SRC—eye—Graves' disease	0.000705	0.0102	CbGeAlD
Vandetanib—ERBB3—adipose tissue—Graves' disease	0.000694	0.01	CbGeAlD
Vandetanib—STK35—thyroid gland—Graves' disease	0.000681	0.00985	CbGeAlD
Vandetanib—SRC—connective tissue—Graves' disease	0.000679	0.00983	CbGeAlD
Vandetanib—ABL2—thyroid gland—Graves' disease	0.000664	0.0096	CbGeAlD
Vandetanib—MKNK1—pituitary gland—Graves' disease	0.000655	0.00947	CbGeAlD
Vandetanib—MKNK1—adipose tissue—Graves' disease	0.000652	0.00943	CbGeAlD
Vandetanib—KDR—eye—Graves' disease	0.000648	0.00938	CbGeAlD
Vandetanib—EGFR—thyroid gland—Graves' disease	0.000648	0.00937	CbGeAlD
Vandetanib—RET—pituitary gland—Graves' disease	0.000647	0.00936	CbGeAlD
Vandetanib—FGR—pituitary gland—Graves' disease	0.000647	0.00936	CbGeAlD
Vandetanib—AXL—pituitary gland—Graves' disease	0.000644	0.00932	CbGeAlD
Vandetanib—FGR—adipose tissue—Graves' disease	0.000644	0.00932	CbGeAlD
Vandetanib—LCK—adipose tissue—Graves' disease	0.000644	0.00932	CbGeAlD
Vandetanib—AXL—adipose tissue—Graves' disease	0.000641	0.00928	CbGeAlD
Vandetanib—FLT4—thyroid gland—Graves' disease	0.000631	0.00914	CbGeAlD
Vandetanib—RIPK2—thyroid gland—Graves' disease	0.000628	0.00909	CbGeAlD
Vandetanib—VEGFA—thyroid gland—Graves' disease	0.000626	0.00906	CbGeAlD
Vandetanib—KDR—connective tissue—Graves' disease	0.000625	0.00904	CbGeAlD
Vandetanib—FMO3—pituitary gland—Graves' disease	0.000624	0.00904	CbGeAlD
Vandetanib—FMO1—thyroid gland—Graves' disease	0.000623	0.00901	CbGeAlD
Vandetanib—FMO3—adipose tissue—Graves' disease	0.000622	0.009	CbGeAlD
Vandetanib—SLK—pituitary gland—Graves' disease	0.00062	0.00897	CbGeAlD
Vandetanib—SLK—adipose tissue—Graves' disease	0.000617	0.00893	CbGeAlD
Vandetanib—IRAK4—thyroid gland—Graves' disease	0.000613	0.00887	CbGeAlD
Vandetanib—FYN—pituitary gland—Graves' disease	0.000603	0.00872	CbGeAlD
Vandetanib—ERBB3—thyroid gland—Graves' disease	0.000601	0.0087	CbGeAlD
Vandetanib—FYN—adipose tissue—Graves' disease	0.0006	0.00869	CbGeAlD
Vandetanib—TEK—pituitary gland—Graves' disease	0.000589	0.00852	CbGeAlD
Vandetanib—MAP4K5—pituitary gland—Graves' disease	0.000589	0.00852	CbGeAlD
Vandetanib—MAP4K5—adipose tissue—Graves' disease	0.000587	0.00849	CbGeAlD
Vandetanib—TEK—adipose tissue—Graves' disease	0.000587	0.00849	CbGeAlD
Vandetanib—MKNK1—thyroid gland—Graves' disease	0.000564	0.00817	CbGeAlD
Vandetanib—EPHB6—pituitary gland—Graves' disease	0.000563	0.00815	CbGeAlD
Vandetanib—PDGFRB—eye—Graves' disease	0.000561	0.00812	CbGeAlD
Vandetanib—EPHB6—adipose tissue—Graves' disease	0.000561	0.00811	CbGeAlD
Vandetanib—LCK—thyroid gland—Graves' disease	0.000557	0.00807	CbGeAlD
Vandetanib—FGR—thyroid gland—Graves' disease	0.000557	0.00807	CbGeAlD
Vandetanib—RET—thyroid gland—Graves' disease	0.000557	0.00807	CbGeAlD
Vandetanib—AXL—thyroid gland—Graves' disease	0.000555	0.00803	CbGeAlD
Vandetanib—YES1—pituitary gland—Graves' disease	0.000544	0.00787	CbGeAlD
Vandetanib—YES1—adipose tissue—Graves' disease	0.000542	0.00784	CbGeAlD
Vandetanib—PDGFRB—connective tissue—Graves' disease	0.000541	0.00783	CbGeAlD
Vandetanib—FMO3—thyroid gland—Graves' disease	0.000538	0.00779	CbGeAlD
Vandetanib—STK10—adipose tissue—Graves' disease	0.000537	0.00777	CbGeAlD
Vandetanib—SLK—thyroid gland—Graves' disease	0.000534	0.00773	CbGeAlD
Vandetanib—SRC—adipose tissue—Graves' disease	0.000521	0.00754	CbGeAlD
Vandetanib—FYN—thyroid gland—Graves' disease	0.00052	0.00752	CbGeAlD
Vandetanib—MAP4K5—thyroid gland—Graves' disease	0.000508	0.00735	CbGeAlD
Vandetanib—TEK—thyroid gland—Graves' disease	0.000508	0.00735	CbGeAlD
Vandetanib—ABL1—eye—Graves' disease	0.0005	0.00724	CbGeAlD
Vandetanib—EPHB6—thyroid gland—Graves' disease	0.000485	0.00702	CbGeAlD
Vandetanib—ABL1—connective tissue—Graves' disease	0.000482	0.00698	CbGeAlD
Vandetanib—MAP2K5—pituitary gland—Graves' disease	0.000481	0.00697	CbGeAlD
Vandetanib—KDR—pituitary gland—Graves' disease	0.000481	0.00697	CbGeAlD
Vandetanib—KDR—adipose tissue—Graves' disease	0.000479	0.00694	CbGeAlD
Vandetanib—MAP2K5—adipose tissue—Graves' disease	0.000479	0.00694	CbGeAlD
Vandetanib—YES1—thyroid gland—Graves' disease	0.000469	0.00679	CbGeAlD
Vandetanib—STK10—thyroid gland—Graves' disease	0.000465	0.00672	CbGeAlD
Vandetanib—SRC—thyroid gland—Graves' disease	0.000451	0.00653	CbGeAlD
Vandetanib—Alopecia—Methimazole—Graves' disease	0.000434	0.0398	CcSEcCtD
Vandetanib—Haemoglobin—Propylthiouracil—Graves' disease	0.00042	0.0385	CcSEcCtD
Vandetanib—Haemorrhage—Propylthiouracil—Graves' disease	0.000418	0.0383	CcSEcCtD
Vandetanib—PDGFRB—pituitary gland—Graves' disease	0.000417	0.00603	CbGeAlD
Vandetanib—MAP2K5—thyroid gland—Graves' disease	0.000415	0.006	CbGeAlD
Vandetanib—KDR—thyroid gland—Graves' disease	0.000415	0.006	CbGeAlD
Vandetanib—PDGFRB—adipose tissue—Graves' disease	0.000415	0.006	CbGeAlD
Vandetanib—ABL1—pituitary gland—Graves' disease	0.000371	0.00537	CbGeAlD
Vandetanib—ABL1—adipose tissue—Graves' disease	0.00037	0.00535	CbGeAlD
Vandetanib—Alopecia—Propylthiouracil—Graves' disease	0.000369	0.0338	CcSEcCtD
Vandetanib—Arthralgia—Methimazole—Graves' disease	0.000364	0.0334	CcSEcCtD
Vandetanib—PDGFRB—thyroid gland—Graves' disease	0.000359	0.0052	CbGeAlD
Vandetanib—Dysgeusia—Propylthiouracil—Graves' disease	0.000356	0.0326	CcSEcCtD
Vandetanib—Oedema—Methimazole—Graves' disease	0.000349	0.032	CcSEcCtD
Vandetanib—Thrombocytopenia—Methimazole—Graves' disease	0.000342	0.0313	CcSEcCtD
Vandetanib—ABL1—thyroid gland—Graves' disease	0.00032	0.00463	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Methimazole—Graves' disease	0.000318	0.0291	CcSEcCtD
Vandetanib—Paraesthesia—Methimazole—Graves' disease	0.000314	0.0287	CcSEcCtD
Vandetanib—Arthralgia—Propylthiouracil—Graves' disease	0.00031	0.0284	CcSEcCtD
Vandetanib—Dyspepsia—Methimazole—Graves' disease	0.000307	0.0282	CcSEcCtD
Vandetanib—Oedema—Propylthiouracil—Graves' disease	0.000297	0.0272	CcSEcCtD
Vandetanib—Thrombocytopenia—Propylthiouracil—Graves' disease	0.000291	0.0266	CcSEcCtD
Vandetanib—ABCC1—pituitary gland—Graves' disease	0.000283	0.00409	CbGeAlD
Vandetanib—ABCC1—adipose tissue—Graves' disease	0.000282	0.00408	CbGeAlD
Vandetanib—Body temperature increased—Methimazole—Graves' disease	0.000276	0.0253	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.000271	0.0248	CcSEcCtD
Vandetanib—Paraesthesia—Propylthiouracil—Graves' disease	0.000267	0.0244	CcSEcCtD
Vandetanib—Dyspepsia—Propylthiouracil—Graves' disease	0.000261	0.0239	CcSEcCtD
Vandetanib—Pruritus—Methimazole—Graves' disease	0.000247	0.0226	CcSEcCtD
Vandetanib—ABCC1—thyroid gland—Graves' disease	0.000244	0.00353	CbGeAlD
Vandetanib—Body temperature increased—Propylthiouracil—Graves' disease	0.000235	0.0215	CcSEcCtD
Vandetanib—ABCG2—pituitary gland—Graves' disease	0.000234	0.00339	CbGeAlD
Vandetanib—ABCG2—adipose tissue—Graves' disease	0.000233	0.00337	CbGeAlD
Vandetanib—Vomiting—Methimazole—Graves' disease	0.000222	0.0203	CcSEcCtD
Vandetanib—Rash—Methimazole—Graves' disease	0.00022	0.0202	CcSEcCtD
Vandetanib—Dermatitis—Methimazole—Graves' disease	0.00022	0.0202	CcSEcCtD
Vandetanib—Headache—Methimazole—Graves' disease	0.000219	0.02	CcSEcCtD
Vandetanib—Pruritus—Propylthiouracil—Graves' disease	0.00021	0.0192	CcSEcCtD
Vandetanib—Nausea—Methimazole—Graves' disease	0.000207	0.019	CcSEcCtD
Vandetanib—ABCG2—thyroid gland—Graves' disease	0.000202	0.00292	CbGeAlD
Vandetanib—Vomiting—Propylthiouracil—Graves' disease	0.000189	0.0173	CcSEcCtD
Vandetanib—Rash—Propylthiouracil—Graves' disease	0.000187	0.0172	CcSEcCtD
Vandetanib—Dermatitis—Propylthiouracil—Graves' disease	0.000187	0.0171	CcSEcCtD
Vandetanib—Headache—Propylthiouracil—Graves' disease	0.000186	0.017	CcSEcCtD
Vandetanib—Nausea—Propylthiouracil—Graves' disease	0.000176	0.0162	CcSEcCtD
Vandetanib—MKNK1—Signaling Pathways—IL2RA—Graves' disease	2.08e-05	0.000373	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—HLA-DQB1—Graves' disease	2.08e-05	0.000373	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—HLA-A—Graves' disease	2.08e-05	0.000373	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—ICAM1—Graves' disease	2.08e-05	0.000372	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL2RA—Graves' disease	2.08e-05	0.000372	CbGpPWpGaD
Vandetanib—LCK—Cytokine Signaling in Immune system—IFNG—Graves' disease	2.07e-05	0.000371	CbGpPWpGaD
Vandetanib—BLK—Immune System—HLA-A—Graves' disease	2.06e-05	0.000369	CbGpPWpGaD
Vandetanib—FGR—Immune System—HLA-A—Graves' disease	2.05e-05	0.000368	CbGpPWpGaD
Vandetanib—SRC—Disease—B3GNT2—Graves' disease	2.05e-05	0.000367	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—HLA-B—Graves' disease	2.04e-05	0.000365	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—HLA-A—Graves' disease	2.04e-05	0.000365	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IFIH1—Graves' disease	2.03e-05	0.000363	CbGpPWpGaD
Vandetanib—ALB—Selenium Micronutrient Network—TNF—Graves' disease	2.02e-05	0.000362	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HLA-DQB1—Graves' disease	2.01e-05	0.00036	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—HLA-A—Graves' disease	2.01e-05	0.000359	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—CD4—Graves' disease	2.01e-05	0.000359	CbGpPWpGaD
Vandetanib—YES1—Immune System—HLA-DQB1—Graves' disease	1.99e-05	0.000357	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—HLA-DRB1—Graves' disease	1.96e-05	0.000351	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—IL2RA—Graves' disease	1.96e-05	0.00035	CbGpPWpGaD
Vandetanib—LCK—Immune System—IFIH1—Graves' disease	1.95e-05	0.000349	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—HLA-B—Graves' disease	1.95e-05	0.000349	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—CD8A—Graves' disease	1.95e-05	0.000348	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HLA-E—Graves' disease	1.91e-05	0.000343	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL2RA—Graves' disease	1.91e-05	0.000342	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—HLA-DRB1—Graves' disease	1.9e-05	0.000341	CbGpPWpGaD
Vandetanib—MKNK1—Disease—CD4—Graves' disease	1.9e-05	0.00034	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—HLA-A—Graves' disease	1.89e-05	0.000338	CbGpPWpGaD
Vandetanib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	1.89e-05	0.000338	CbGpPWpGaD
Vandetanib—BLK—Immune System—HLA-DRB1—Graves' disease	1.88e-05	0.000337	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—ICAM1—Graves' disease	1.88e-05	0.000337	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—HLA-B—Graves' disease	1.88e-05	0.000336	CbGpPWpGaD
Vandetanib—FGR—Immune System—HLA-DRB1—Graves' disease	1.88e-05	0.000336	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—B3GNT2—Graves' disease	1.88e-05	0.000336	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—CD8A—Graves' disease	1.88e-05	0.000336	CbGpPWpGaD
Vandetanib—LYN—Immune System—HLA-E—Graves' disease	1.87e-05	0.000335	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—HLA-B—Graves' disease	1.87e-05	0.000335	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CD40—Graves' disease	1.87e-05	0.000335	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HLA-E—Graves' disease	1.86e-05	0.000334	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—HLA-DRB1—Graves' disease	1.86e-05	0.000334	CbGpPWpGaD
Vandetanib—YES1—Immune System—CD8A—Graves' disease	1.86e-05	0.000333	CbGpPWpGaD
Vandetanib—LCK—Cytokine Signaling in Immune system—IL1B—Graves' disease	1.85e-05	0.000331	CbGpPWpGaD
Vandetanib—FYN—Immune System—HLA-E—Graves' disease	1.84e-05	0.00033	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CTLA4—Graves' disease	1.84e-05	0.00033	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—CD4—Graves' disease	1.83e-05	0.000329	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—HLA-DRB1—Graves' disease	1.83e-05	0.000328	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—CXCL10—Graves' disease	1.83e-05	0.000328	CbGpPWpGaD
Vandetanib—LYN—Immune System—CD40—Graves' disease	1.83e-05	0.000328	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—ICAM1—Graves' disease	1.83e-05	0.000327	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD40—Graves' disease	1.82e-05	0.000326	CbGpPWpGaD
Vandetanib—BLK—Immune System—ICAM1—Graves' disease	1.81e-05	0.000324	CbGpPWpGaD
Vandetanib—LYN—Immune System—CTLA4—Graves' disease	1.8e-05	0.000323	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HLA-B—Graves' disease	1.8e-05	0.000323	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD40—Graves' disease	1.8e-05	0.000323	CbGpPWpGaD
Vandetanib—FGR—Immune System—ICAM1—Graves' disease	1.8e-05	0.000323	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CTLA4—Graves' disease	1.8e-05	0.000322	CbGpPWpGaD
Vandetanib—YES1—Immune System—HLA-B—Graves' disease	1.79e-05	0.000321	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—ICAM1—Graves' disease	1.79e-05	0.00032	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HLA-DQB1—Graves' disease	1.78e-05	0.000318	CbGpPWpGaD
Vandetanib—FYN—Immune System—CTLA4—Graves' disease	1.78e-05	0.000318	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—CD4—Graves' disease	1.76e-05	0.000316	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—ICAM1—Graves' disease	1.76e-05	0.000315	CbGpPWpGaD
Vandetanib—ERBB3—Disease—HLA-A—Graves' disease	1.74e-05	0.000312	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—HLA-A—Graves' disease	1.73e-05	0.000311	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—IL2RA—Graves' disease	1.73e-05	0.00031	CbGpPWpGaD
Vandetanib—SRC—Immune System—IFIH1—Graves' disease	1.73e-05	0.000309	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—HLA-DRB1—Graves' disease	1.73e-05	0.000309	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL2RA—Graves' disease	1.68e-05	0.0003	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CXCL10—Graves' disease	1.68e-05	0.0003	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TSHR—Graves' disease	1.67e-05	0.000299	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HLA-A—Graves' disease	1.67e-05	0.000299	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—HLA-B—Graves' disease	1.66e-05	0.000298	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—CD8A—Graves' disease	1.66e-05	0.000297	CbGpPWpGaD
Vandetanib—YES1—Immune System—HLA-A—Graves' disease	1.66e-05	0.000297	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—ICAM1—Graves' disease	1.66e-05	0.000297	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TSHR—Graves' disease	1.64e-05	0.000293	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CXCL10—Graves' disease	1.63e-05	0.000293	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CXCL10—Graves' disease	1.62e-05	0.000289	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TSHR—Graves' disease	1.61e-05	0.000289	CbGpPWpGaD
Vandetanib—SRC—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	1.61e-05	0.000289	CbGpPWpGaD
Vandetanib—KDR—Developmental Biology—TNF—Graves' disease	1.6e-05	0.000287	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HLA-B—Graves' disease	1.6e-05	0.000286	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HLA-E—Graves' disease	1.59e-05	0.000285	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—HLA-DRB1—Graves' disease	1.58e-05	0.000284	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—IFNG—Graves' disease	1.58e-05	0.000283	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD40—Graves' disease	1.56e-05	0.000279	CbGpPWpGaD
Vandetanib—LCK—Immune System—HLA-E—Graves' disease	1.54e-05	0.000275	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CTLA4—Graves' disease	1.53e-05	0.000275	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GC—Graves' disease	1.53e-05	0.000274	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—CD4—Graves' disease	1.53e-05	0.000273	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HLA-DRB1—Graves' disease	1.53e-05	0.000273	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—CXCL10—Graves' disease	1.52e-05	0.000273	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—ICAM1—Graves' disease	1.52e-05	0.000272	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HLA-DQB1—Graves' disease	1.52e-05	0.000272	CbGpPWpGaD
Vandetanib—YES1—Immune System—HLA-DRB1—Graves' disease	1.52e-05	0.000271	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD40—Graves' disease	1.5e-05	0.000269	CbGpPWpGaD
Vandetanib—LYN—Immune System—HLA-DQB1—Graves' disease	1.49e-05	0.000266	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HLA-A—Graves' disease	1.48e-05	0.000265	CbGpPWpGaD
Vandetanib—LCK—Immune System—CTLA4—Graves' disease	1.48e-05	0.000265	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HLA-DQB1—Graves' disease	1.48e-05	0.000265	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CXCL10—Graves' disease	1.47e-05	0.000263	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—ICAM1—Graves' disease	1.47e-05	0.000262	CbGpPWpGaD
Vandetanib—FYN—Immune System—HLA-DQB1—Graves' disease	1.46e-05	0.000262	CbGpPWpGaD
Vandetanib—YES1—Immune System—ICAM1—Graves' disease	1.45e-05	0.00026	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—TNF—Graves' disease	1.44e-05	0.000258	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—IFNG—Graves' disease	1.43e-05	0.000256	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CXCL10—Graves' disease	1.42e-05	0.000254	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CD8A—Graves' disease	1.42e-05	0.000254	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—IL1B—Graves' disease	1.41e-05	0.000253	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL2RA—Graves' disease	1.4e-05	0.000251	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—CD4—Graves' disease	1.4e-05	0.00025	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TSHR—Graves' disease	1.39e-05	0.000249	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—TNF—Graves' disease	1.39e-05	0.000249	CbGpPWpGaD
Vandetanib—LYN—Immune System—CD8A—Graves' disease	1.39e-05	0.000248	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD8A—Graves' disease	1.38e-05	0.000247	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—CD4—Graves' disease	1.38e-05	0.000247	CbGpPWpGaD
Vandetanib—BLK—Immune System—IFNG—Graves' disease	1.38e-05	0.000246	CbGpPWpGaD
Vandetanib—FGR—Immune System—IFNG—Graves' disease	1.37e-05	0.000246	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—CD4—Graves' disease	1.37e-05	0.000245	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD8A—Graves' disease	1.37e-05	0.000245	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HLA-B—Graves' disease	1.36e-05	0.000244	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—CD4—Graves' disease	1.36e-05	0.000244	CbGpPWpGaD
Vandetanib—SRC—Immune System—HLA-E—Graves' disease	1.36e-05	0.000243	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HLA-DRB1—Graves' disease	1.35e-05	0.000242	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—CD4—Graves' disease	1.35e-05	0.000241	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TSHR—Graves' disease	1.34e-05	0.00024	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—CD4—Graves' disease	1.34e-05	0.00024	CbGpPWpGaD
Vandetanib—LYN—Immune System—HLA-B—Graves' disease	1.33e-05	0.000239	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HLA-B—Graves' disease	1.33e-05	0.000238	CbGpPWpGaD
Vandetanib—BLK—Immune System—CD4—Graves' disease	1.33e-05	0.000238	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD40—Graves' disease	1.33e-05	0.000238	CbGpPWpGaD
Vandetanib—FGR—Immune System—CD4—Graves' disease	1.32e-05	0.000237	CbGpPWpGaD
Vandetanib—FYN—Immune System—HLA-B—Graves' disease	1.31e-05	0.000235	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—CD4—Graves' disease	1.31e-05	0.000235	CbGpPWpGaD
Vandetanib—SRC—Immune System—CTLA4—Graves' disease	1.31e-05	0.000234	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—ICAM1—Graves' disease	1.3e-05	0.000232	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—CD4—Graves' disease	1.29e-05	0.000232	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL2RA—Graves' disease	1.28e-05	0.00023	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL2RA—Graves' disease	1.28e-05	0.000229	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—IL1B—Graves' disease	1.28e-05	0.000228	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HLA-DQB1—Graves' disease	1.26e-05	0.000226	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HLA-A—Graves' disease	1.26e-05	0.000226	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IFNG—Graves' disease	1.26e-05	0.000226	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL2RA—Graves' disease	1.25e-05	0.000224	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL2RA—Graves' disease	1.25e-05	0.000224	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL2RA—Graves' disease	1.24e-05	0.000223	CbGpPWpGaD
Vandetanib—LYN—Immune System—HLA-A—Graves' disease	1.24e-05	0.000221	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL2RA—Graves' disease	1.24e-05	0.000221	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL2RA—Graves' disease	1.23e-05	0.000221	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HLA-A—Graves' disease	1.23e-05	0.00022	CbGpPWpGaD
Vandetanib—BLK—Immune System—IL1B—Graves' disease	1.23e-05	0.00022	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL1B—Graves' disease	1.22e-05	0.000219	CbGpPWpGaD
Vandetanib—LCK—Immune System—HLA-DQB1—Graves' disease	1.22e-05	0.000218	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—CD4—Graves' disease	1.22e-05	0.000218	CbGpPWpGaD
Vandetanib—FYN—Immune System—HLA-A—Graves' disease	1.22e-05	0.000218	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TSHR—Graves' disease	1.19e-05	0.000213	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD8A—Graves' disease	1.18e-05	0.000211	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—IL2RA—Graves' disease	1.17e-05	0.000209	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HLA-A—Graves' disease	1.17e-05	0.000209	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL2RA—Graves' disease	1.16e-05	0.000209	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—CD4—Graves' disease	1.16e-05	0.000208	CbGpPWpGaD
Vandetanib—ALB—Metabolism—B3GNT2—Graves' disease	1.16e-05	0.000207	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HLA-DRB1—Graves' disease	1.15e-05	0.000207	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD8A—Graves' disease	1.14e-05	0.000204	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HLA-B—Graves' disease	1.14e-05	0.000203	CbGpPWpGaD
Vandetanib—LYN—Immune System—HLA-DRB1—Graves' disease	1.13e-05	0.000202	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HLA-DRB1—Graves' disease	1.12e-05	0.000201	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL1B—Graves' disease	1.12e-05	0.000201	CbGpPWpGaD
Vandetanib—ERBB3—Disease—CD4—Graves' disease	1.12e-05	0.000201	CbGpPWpGaD
Vandetanib—FYN—Disease—HLA-A—Graves' disease	1.12e-05	0.000201	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL2RA—Graves' disease	1.12e-05	0.000201	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—CD4—Graves' disease	1.12e-05	0.000201	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—CD4—Graves' disease	1.12e-05	0.0002	CbGpPWpGaD
Vandetanib—FYN—Immune System—HLA-DRB1—Graves' disease	1.11e-05	0.000199	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—ICAM1—Graves' disease	1.11e-05	0.000198	CbGpPWpGaD
Vandetanib—YES1—Immune System—IFNG—Graves' disease	1.11e-05	0.000198	CbGpPWpGaD
Vandetanib—LCK—Immune System—HLA-B—Graves' disease	1.09e-05	0.000196	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL2RA—Graves' disease	1.08e-05	0.000194	CbGpPWpGaD
Vandetanib—LYN—Immune System—ICAM1—Graves' disease	1.08e-05	0.000194	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CXCL10—Graves' disease	1.08e-05	0.000194	CbGpPWpGaD
Vandetanib—ABL1—Immune System—ICAM1—Graves' disease	1.08e-05	0.000193	CbGpPWpGaD
Vandetanib—SRC—Immune System—HLA-DQB1—Graves' disease	1.08e-05	0.000193	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—CD4—Graves' disease	1.08e-05	0.000193	CbGpPWpGaD
Vandetanib—YES1—Immune System—CD4—Graves' disease	1.07e-05	0.000191	CbGpPWpGaD
Vandetanib—FYN—Immune System—ICAM1—Graves' disease	1.07e-05	0.000191	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL2RA—Graves' disease	1.06e-05	0.000191	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CXCL10—Graves' disease	1.06e-05	0.000189	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HLA-A—Graves' disease	1.05e-05	0.000188	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CXCL10—Graves' disease	1.04e-05	0.000187	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—TNF—Graves' disease	1.04e-05	0.000186	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—TNF—Graves' disease	1.03e-05	0.000185	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HLA-A—Graves' disease	1.03e-05	0.000185	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL2RA—Graves' disease	1.03e-05	0.000184	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—TNF—Graves' disease	1.02e-05	0.000183	CbGpPWpGaD
Vandetanib—LCK—Immune System—HLA-A—Graves' disease	1.01e-05	0.000182	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD8A—Graves' disease	1.01e-05	0.00018	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—CD4—Graves' disease	9.93e-06	0.000178	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL1B—Graves' disease	9.87e-06	0.000177	CbGpPWpGaD
Vandetanib—EGFR—Disease—HLA-A—Graves' disease	9.71e-06	0.000174	CbGpPWpGaD
Vandetanib—SRC—Immune System—HLA-B—Graves' disease	9.68e-06	0.000173	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HLA-DRB1—Graves' disease	9.61e-06	0.000172	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—CD4—Graves' disease	9.53e-06	0.000171	CbGpPWpGaD
Vandetanib—LCK—Disease—HLA-A—Graves' disease	9.36e-06	0.000168	CbGpPWpGaD
Vandetanib—LCK—Immune System—HLA-DRB1—Graves' disease	9.26e-06	0.000166	CbGpPWpGaD
Vandetanib—EGFR—Immune System—ICAM1—Graves' disease	9.22e-06	0.000165	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL2RA—Graves' disease	9.08e-06	0.000163	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL10—Graves' disease	9e-06	0.000161	CbGpPWpGaD
Vandetanib—SRC—Immune System—HLA-A—Graves' disease	8.97e-06	0.000161	CbGpPWpGaD
Vandetanib—LCK—Immune System—ICAM1—Graves' disease	8.89e-06	0.000159	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—TNF—Graves' disease	8.83e-06	0.000158	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL10—Graves' disease	8.67e-06	0.000155	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IFNG—Graves' disease	8.43e-06	0.000151	CbGpPWpGaD
Vandetanib—SRC—Disease—HLA-A—Graves' disease	8.29e-06	0.000148	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL2RA—Graves' disease	8.26e-06	0.000148	CbGpPWpGaD
Vandetanib—LYN—Immune System—IFNG—Graves' disease	8.25e-06	0.000148	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GC—Graves' disease	8.25e-06	0.000148	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IFNG—Graves' disease	8.21e-06	0.000147	CbGpPWpGaD
Vandetanib—SRC—Immune System—HLA-DRB1—Graves' disease	8.2e-06	0.000147	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CD4—Graves' disease	8.14e-06	0.000146	CbGpPWpGaD
Vandetanib—FYN—Immune System—IFNG—Graves' disease	8.12e-06	0.000145	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL2RA—Graves' disease	8.09e-06	0.000145	CbGpPWpGaD
Vandetanib—LYN—Immune System—CD4—Graves' disease	7.97e-06	0.000143	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL2RA—Graves' disease	7.96e-06	0.000143	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD4—Graves' disease	7.93e-06	0.000142	CbGpPWpGaD
Vandetanib—SRC—Immune System—ICAM1—Graves' disease	7.87e-06	0.000141	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD4—Graves' disease	7.85e-06	0.000141	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL10—Graves' disease	7.68e-06	0.000137	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—TNF—Graves' disease	7.53e-06	0.000135	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL1B—Graves' disease	7.52e-06	0.000135	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—CD4—Graves' disease	7.51e-06	0.000135	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL1B—Graves' disease	7.36e-06	0.000132	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL1B—Graves' disease	7.33e-06	0.000131	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL1B—Graves' disease	7.25e-06	0.00013	CbGpPWpGaD
Vandetanib—FYN—Disease—CD4—Graves' disease	7.24e-06	0.00013	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IFNG—Graves' disease	7.02e-06	0.000126	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2RA—Graves' disease	6.88e-06	0.000123	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD4—Graves' disease	6.78e-06	0.000121	CbGpPWpGaD
Vandetanib—LCK—Immune System—IFNG—Graves' disease	6.76e-06	0.000121	CbGpPWpGaD
Vandetanib—ABCC1—Disease—CD4—Graves' disease	6.64e-06	0.000119	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2RA—Graves' disease	6.63e-06	0.000119	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD4—Graves' disease	6.53e-06	0.000117	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL1B—Graves' disease	6.26e-06	0.000112	CbGpPWpGaD
Vandetanib—EGFR—Disease—CD4—Graves' disease	6.26e-06	0.000112	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—B3GNT2—Graves' disease	6.25e-06	0.000112	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL1B—Graves' disease	6.03e-06	0.000108	CbGpPWpGaD
Vandetanib—LCK—Disease—CD4—Graves' disease	6.03e-06	0.000108	CbGpPWpGaD
Vandetanib—SRC—Immune System—IFNG—Graves' disease	5.99e-06	0.000107	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2RA—Graves' disease	5.87e-06	0.000105	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD4—Graves' disease	5.78e-06	0.000104	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL1B—Graves' disease	5.34e-06	9.56e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CD4—Graves' disease	5.34e-06	9.56e-05	CbGpPWpGaD
